Extending the lives of patients suffering from CNS disease
At EnClear Therapies, our goal is to improve and extend the lives of patients with a wide variety of CNS disease through precision dosing. We are building an Integrated Neurotechnology Business utilizing our proprietary EnTrega CSF Platform to create a pipeline of significant near-term, patient focused, opportunities. Launching into neuro-oncology, while leveraging partnerships to expand into neurodegenerative, lysosomal storage & autoimmune diseases.
Our mission is to improve and extend the lives of patients suffering from central nervous system (CNS) disorders such as neurodegenerative diseases and CNS malignancies.
Our opportunity is to utilize our EnTrega CSF Platform to provide precision dosing to areas of the CNS most benefited by both existing & next-generation therapeutics.
Our strategy is two-fold:
1) Launch into neuro oncology, immediately addressing $1.2B market need.
2) Leverage partnerships to expand our portfolio with next gen, personalized medicine into neurodegenerative, lysosomal storage & autoimmune diseases.
EnTrega CSF PLATFORM
Closed loop CSF control & integrated ML/AI, the EnClear Therapies EnTrega CSF platform provides Precision Dosing of CNS based therapeutics to obtain efficacious levels, while reducing risk of severe side effects and peripheral toxicity.